home
Bringing New Horizons to Therapy

Investor Information

Event: August 28, 2014

EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.






IR Contact

Stock Information



NASDAQ : EDAP
Last Price : 1.47
Change : 0.03 up 2.083%
Day High : 1.50
Day Low : 1.40
Year High : 6.05
Year Low : 1.36
Volume : 211,900